AJAY SHESHADRI to Retrospective Studies
This is a "connection" page, showing publications AJAY SHESHADRI has written about Retrospective Studies.
Connection Strength
0.635
-
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clin Lung Cancer. 2024 Nov; 25(7):624-633.e2.
Score: 0.047
-
Association of Preoperative Lung Function with Complications after Lobectomy Using Race-Neutral and Race-Specific Normative Equations. Ann Am Thorac Soc. 2024 Jan; 21(1):38-46.
Score: 0.046
-
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. 2023 Nov 02; 28(11):e1065-e1074.
Score: 0.045
-
Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol). 2023 10; 35(10):630-639.
Score: 0.044
-
Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease. Curr Opin Pulm Med. 2023 07 01; 29(4):248-255.
Score: 0.044
-
Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 03; 29(3):204.e1-204.e7.
Score: 0.042
-
Lung Function Monitoring After Lung Transplantation and Allogeneic Hematopoietic Stem Cell Transplantation. Clin Ther. 2022 05; 44(5):755-765.e6.
Score: 0.041
-
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745.
Score: 0.040
-
The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv. 2022 03 08; 6(5):1566-1576.
Score: 0.040
-
The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ. 2022 Jan-Dec; 25(1):650-659.
Score: 0.040
-
Pulmonary Function Testing in Patients with Tracheostomies: Feasibility and Technical Considerations. Lung. 2021 06; 199(3):307-310.
Score: 0.038
-
Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection. Transpl Infect Dis. 2019 Aug; 21(4):e13105.
Score: 0.033
-
Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. PLoS One. 2018; 13(5):e0197418.
Score: 0.031
-
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152.
Score: 0.012
-
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
Score: 0.011
-
Utility of Bronchoalveolar Lavage for the Diagnosis and Management of COVID-19 in Patients With Cancer. J Infect Dis. 2023 11 28; 228(11):1549-1558.
Score: 0.011
-
Quantitative CT Characteristics of Cluster Phenotypes in the Severe Asthma Research Program Cohorts. Radiology. 2022 08; 304(2):450-459.
Score: 0.010
-
Airway disease in hematologic malignancies. Expert Rev Respir Med. 2022 03; 16(3):303-313.
Score: 0.010
-
Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2021 07; 27(7):616.e1-616.e6.
Score: 0.009
-
Complications following symptom-limited thoracentesis using suction. Eur Respir J. 2020 11; 56(5).
Score: 0.009
-
Routine Microbiologic Studies of Pleural Fluid Specimens in Cancer Patients. Am J Med. 2020 02; 133(2):240-244.
Score: 0.008
-
Predicting Lung Function Following Lobectomy: A New Method to Adjust for Inherent Selection Bias. Respiration. 2018; 96(5):434-445.
Score: 0.008
-
Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis. 2018 Dec; 20(6):e12994.
Score: 0.008
-
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
Score: 0.007